ERBB2 and breast cancer: Alpelisib, a selective inhibitor of the p110α subunit of PI3K (3), has demonstrated substantial clinical efficacy in hormone receptor (HR)-positive, HER2/erbB2-negative breast cancers harboring PIK3CA mutations (4–6).